{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:07Z","timestamp":1792417387888,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives:<\/jats:title>\n                    <jats:p>Gut inflammation and microbiota dysregulation are increasingly implicated in Parkinson\u2019s disease (PD). Fecal calprotectin, a neutrophil-derived protein and marker of intestinal inflammation, may serve as a non-invasive indicator of gut\u2013brain axis dysfunction in parkinsonian disorders. To evaluate fecal calprotectin levels in idiopathic Parkinson\u2019s disease (IPD) and atypical parkinsonian syndromes\u2014progressive supranuclear palsy (PSP) and multiple system atrophy (MSA)\u2014and examine their relationship with motor and non-motor features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this case-control study, 130 patients (IPD = 94, PSP = 23, MSA = 13) and 80 age- and sex-matched healthy controls were enrolled. All participants underwent detailed clinical evaluation, including the movement disorder society\u2013unified Parkinson\u2019s disease rating scale (MDS-UPDRS), Hoehn and Yahr staging, the non-motor symptoms scale (NMSS), the Rome IV criteria for constipation, and the Montreal cognitive assessment (MoCA). Fecal calprotectin (\u03bcg\/g stool) was quantified using enzyme-linked immunosorbent assay and correlated with clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Mean fecal calprotectin was significantly higher in IPD and PSP than in controls (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), whereas MSA showed no significant difference. Elevated fecal calprotectin correlated positively with total NMSS scores (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      \u2248 0.3,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) and inversely with MoCA scores, indicating a greater non-motor symptom burden and poorer cognitive performance. No significant correlation was observed with MDS-UPDRS motor scores. Among the NMSS domains, sleep\/fatigue, mood\/apathy, perceptual problems, memory, and sexual domains exhibited the strongest associations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Fecal calprotectin is elevated in IPD and PSP and is more strongly associated with non-motor than motor manifestations. These findings support intestinal inflammation as a contributor to parkinsonian pathophysiology and highlight fecal calprotectin as a potential biomarker of gut\u2013brain axis dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_195_26","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:00:10Z","timestamp":1791604810000},"page":"743-749","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Association of Fecal Calprotectin with Motor and Nonmotor Features in Idiopathic Parkinson\u2019s Disease and Atypical Parkinsonism"],"prefix":"10.4103","volume":"29","author":[{"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam K","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and PET\/CT, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalesh","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Lal","sequence":"additional","affiliation":[{"name":"Department of Neurology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"R1-20261019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of Synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol Neurodegener"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ncl.2024.12.008","article-title":"Non-motor symptoms and treatments in Parkinson's disease","volume":"43","author":"Goldman","year":"2025","journal-title":"Neurol Clin"},{"key":"R4-20261019","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","article-title":"Parkinson's disease: A dual-hit hypothesis","volume":"33","author":"Hawkes","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"114574","DOI":"10.1016\/j.bbr.2023.114574","article-title":"Gut-to-brain spreading of pathology in synucleinopathies: A focus on molecular signalling mediators","volume":"452","author":"Schmitt","year":"2023","journal-title":"Behav Brain Res"},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00415-022-11347-w","article-title":"Autonomic dysfunction in progressive supranuclear palsy","volume":"270","author":"Baschieri","year":"2023","journal-title":"J Neurol"},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01743-1","article-title":"Microbiota\u2013gut\u2013brain axis and its therapeutic applications in neurodegenerative diseases","volume":"9","author":"Loh","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"R8-20261019","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/mdc3.70029","article-title":"The gut-brain axis in Parkinson disease: Emerging concepts and therapeutic implications","volume":"12","author":"Menozzi","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"R9-20261019","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fnins.2019.00992","article-title":"Fecal calprotectin as a marker of the gut immune system activation is elevated in Parkinson's disease","volume":"13","author":"Mulak","year":"2019","journal-title":"Front Neurosci"},{"key":"R10-20261019","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14802\/jmd.21085","article-title":"Fecal calprotectin in Parkinson's disease and multiple system atrophy","volume":"15","author":"Hor","year":"2022","journal-title":"J Mov Disord"},{"key":"R11-20261019","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.parkreldis.2018.02.022","article-title":"Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease","volume":"50","author":"Schwiertz","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"R12-20261019","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"R13-20261019","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"R14-20261019","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The movement disorder society criteria for the diagnosis of multiple system atrophy","volume":"37","author":"Wenning","year":"2022","journal-title":"Mov Disord"},{"key":"R15-20261019","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mds.25383","article-title":"How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale","volume":"28","author":"Stebbins","year":"2013","journal-title":"Mov Disord"},{"key":"R16-20261019","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement disorder society UPDRS revision task force (2008) movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"R17-20261019","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/mds.25181","article-title":"The unified multiple system atrophy rating scale: Intrarater reliability","volume":"27","author":"Krismer","year":"2012","journal-title":"Mov Disord"},{"key":"R18-20261019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/mds.27964","article-title":"The progressive supranuclear palsy clinical deficits scale","volume":"35","author":"Piot","year":"2020","journal-title":"Mov Disord"},{"key":"R19-20261019","doi-asserted-by":"crossref","first-page":"871414","DOI":"10.3389\/fpsyt.2022.871414","article-title":"Cognitive impairment and its associated factors in older adults living in high and low altitude areas: A comparative study","volume":"13","author":"Liu","year":"2022","journal-title":"Front Psychiatry"},{"issue":"Suppl 2","key":"R20-20261019","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2008.02212.x","article-title":"Quantitation of non-motor symptoms in Parkinson's disease","volume":"15","author":"Chaudhuri","year":"2008","journal-title":"Eur J Neurol"},{"key":"R21-20261019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1258\/acb.2009.009061","article-title":"Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers","volume":"47","author":"Joshi","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"R22-20261019","doi-asserted-by":"crossref","first-page":"689723","DOI":"10.3389\/fnins.2021.689723","article-title":"Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in Parkinson's disease","volume":"15","author":"Dumitrescu","year":"2021","journal-title":"Front Neurosci"},{"key":"R23-20261019","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3233\/JPD-160991","article-title":"The potential role of gut-derived inflammation in multiple system atrophy","volume":"7","author":"Engen","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"R24-20261019","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fnins.2019.01102","article-title":"Alterations of the gut microbiota in multiple system atrophy patients","volume":"13","author":"Wan","year":"2019","journal-title":"Front Neurosci"},{"key":"R25-20261019","doi-asserted-by":"crossref","first-page":"101888","DOI":"10.1016\/j.eclinm.2023.101888","article-title":"Efficacy of faecal microbiota transplantation in patients with progressive supranuclear palsy-Richardson's syndrome: A phase 2, single centre, randomised clinical trial","volume":"58","author":"Tian","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R26-20261019","doi-asserted-by":"crossref","first-page":"782082","DOI":"10.3389\/fnagi.2021.782082","article-title":"The Gut\u2013Brain axis and its relation to Parkinson's disease: A review","volume":"13","author":"Klann","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"R27-20261019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2016.03.012","article-title":"Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms","volume":"27","author":"Felice","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"R28-20261019","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/medicina59071240","article-title":"Calprotectin, biomarker of depression in patients with inflammatory bowel disease?","volume":"59","author":"Iordache","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R29-20261019","doi-asserted-by":"crossref","first-page":"106948","DOI":"10.1016\/j.parkreldis.2024.106948","article-title":"Association of intestinal inflammation and permeability markers with clinical manifestations of Parkinson's disease","volume":"123","author":"Rajkovaca Latic","year":"2024","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_195_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:01:22Z","timestamp":1792414882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_195_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_195_26","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}